Disease Patterns of Ankylosing Spondylitis Associated Treatment Patterns and Drug Utilization among Affected Patients: Disease Patterns of Ankylosing Spondylitis

Muhammad Umer Rashid; Amina Khurshid; Hassan Shaukat; Fahd Farooq Ashraf; Muhammad Haseeb Lodhi; Amir Naveed; Muhammad Farrukh Habib

doi:10.54393/pjhs.v5i06.1376

Authors

Muhammad Umer Rashid Department of General Medicine, Pakistan Emirates Military Hospital, Rawalpindi, Pakistan
Amina Khurshid Department of General Medicine, Pakistan Emirates Military Hospital, Rawalpindi, Pakistan
Hassan Shaukat Department of General Medicine, Pakistan Emirates Military Hospital, Rawalpindi, Pakistan
Fahd Farooq Ashraf Department of General Medicine, Pakistan Emirates Military Hospital, Rawalpindi, Pakistan
Muhammad Haseeb Lodhi Department of General Medicine, Pakistan Emirates Military Hospital, Rawalpindi, Pakistan
Amir Naveed Department of Forensic Medicine, Amna Inayat Medical College, Sheikhupura, Pakistan
Muhammad Farrukh Habib Department of Management Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i06.1376

Keywords:

Ankylosing Spondylitis, Autoimmune Disease, Axial Skeleton, Disease Patterns

Abstract

Ankylosing Spondylitis is disease with significant morbidity. With biological DMARDs, treatment is revolutionized compared to conventional options. The article will discuss disease pattern, risk factors and treatment response of various drugs on this disease. Objective: To evaluate the prevalence, risk factors, treatment patterns, and drug utilization associated with Ankylosing Spondylitis (AS) among patients in clinical practice. Methods: This cohort study was done at territory care hospital in Rawalpindi from June 23 to December 23. Data comprised of methods to identify AS, particular tests used to verify diagnosis, numerical and clinical traits of patients included. Study also peruse percentage of patients identified as HLA-B27 positive, Time elapsed between initial symptom appearance and clinical diagnosis of AS, satisfaction of classification criteria and treatment strategies employed, such as advanced therapies for controlling AS disease activity. Results: Mean values for current disease occurrences and functional index outcomes were 3.3 ± 2.1 and 1.8 ± 1.09 in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) were used, respectively. Patients in study received treatment with adalimumab (43%) and Infliximab (27%) for an average period of 3.1 ± 2.1 years. Treatment satisfaction showed convenience domain had lowest score (4.2), whereas scores for side effects, effectiveness, and global satisfaction were 93.7, 75.41, and 73.81, respectively. Conclusions: Among bDMARDS adalimumab was most administered followed by Infliximab. Better therapeutics have improved patient satisfaction. Research revealed a significant decrease in productivity as a result of AS

References

Ebrahimiadib N, Berijani S, Ghahari M, Pahlaviani FG. Ankylosing spondylitis. Journal of Ophthalmic & Vision Research. 2021 Jul; 16(3): 462. doi: 10.18502/jovr.v16i3.9440. DOI: https://doi.org/10.18502/jovr.v16i3.9440

Zhu W, He X, Cheng K, Zhang L, Chen D, Wang X et al. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Research. 2019 Aug; 7(1): 22. doi: 10.1038/s41413-019-0057-8. DOI: https://doi.org/10.1038/s41413-019-0057-8

Arévalo M, Gratacós Masmitjà J, Moreno M, Calvet J, Orellana C, Ruiz D et al. Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the Regisponser database. Arthritis Research & Therapy. 2018 Dec; 20: 1-6. doi: 10.1186/s13075-018-1724-7. DOI: https://doi.org/10.1186/s13075-018-1724-7

Webers C, Ramiro S, Landewé R, van der Heijde D, Van den Bosch F, Dougados M et al. Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. Rheumatic and Musculoskeletal Diseases Open. 2018 Nov; 4(2): e000766. doi: 10.1136/rmdopen-2018-000766. DOI: https://doi.org/10.1136/rmdopen-2018-000766

Proft F and Poddubnyy D. Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria. Therapeutic Advances in Musculoskeletal Disease. 2018 Jun; 10(5-6): 129-39. doi: 10.1177/1759720X18773726. DOI: https://doi.org/10.1177/1759720X18773726

Packham J. Optimizing outcomes for ankylosing spondylitis and axial spondyloarthritis patients: a holistic approach to care. Rheumatology. 2018 Nov; 57(6): vi29-34. doi: 10.1093/rheumatology/key200. DOI: https://doi.org/10.1093/rheumatology/key200

Khan MA and Akkoc N. Ankylosing Spondylitis-Axial Spondyloarthritis. In: Professional Communications. 2nd Edition. Oxford University Press; 2023. doi: 10.1093/oso/9780198864158.001.0001. DOI: https://doi.org/10.1093/oso/9780198864158.001.0001

Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology. 2014 Apr; 53(4): 650-7. doi: 10.1093/rheumatology/ket387. DOI: https://doi.org/10.1093/rheumatology/ket387

Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. New England Journal of Medicine. 2016 Jun; 374(26): 2563-74. doi: 10.1056/NEJMra1406182. DOI: https://doi.org/10.1056/NEJMra1406182

Yates M, Keat A, Gaffney K. Do low-dose anti-TNF regimens have a role in patients with ankylosing spondylitis?. Rheumatology. 2016 May; 55(5): 769-72. doi: 10.1093/rheumatology/kev411. DOI: https://doi.org/10.1093/rheumatology/kev411

Acurcio FD, Guerra Junior AA, da Silva MR, Pereira RG, Godman B, Bennie M et al. Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study. Current Medical Research and Opinion. 2020 Apr; 36(4): 677-86. doi: 10.1080/03007995.2020.1722945. DOI: https://doi.org/10.1080/03007995.2020.1722945

Lie E, Lindström U, Zverkova-Sandström T, Olsen IC, Forsblad-d'Elia H, Askling J et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Annals of the Rheumatic Diseases. 2017 Sep; 76(9): 1515-21. doi: 10.1136/annrheumdis-2016-210931. DOI: https://doi.org/10.1136/annrheumdis-2016-210931

Walsh JA, Adejoro O, Chastek B, Park Y. Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. Journal of Comparative Effectiveness Research. 2018 Apr; 7(4): 369-80. doi: 10.2217/cer-2017-0076. DOI: https://doi.org/10.2217/cer-2017-0076

Lee MY, Shin JY, Park SY, Kim D, Cha HS, Lee EK. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: an analysis of the South Korean National Health Insurance Database. InSeminars in Arthritis and Rheumatism 2018 Feb; 47(4): 485-491. doi: 10.1016/j.semarthrit.2017.08.007. DOI: https://doi.org/10.1016/j.semarthrit.2017.08.007

Van Der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases. 2017 Jun; 76(6): 978-91. doi: 10.1136/annrheumdis-2016-210770. DOI: https://doi.org/10.1136/annrheumdis-2016-210770

Byun DW, Moon SH, Kim T, Lee HH, Park HM, Kang MI et al. Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea. Journal of Bone and Mineral Metabolism. 2019 May; 37: 563-72. doi: 10.1007/s00774-018-0956-6. DOI: https://doi.org/10.1007/s00774-018-0956-6

Oh S, Kim JS, Oh YS, Shin DG, Pak HN, Hwang GS et al. Quality of anticoagulation and treatment satisfaction in patients with non-valvular atrial fibrillation treated with Vitamin K antagonist: result from the Korean atrial fibrillation investigation II. Journal of Korean Medical Science. 2018 Dec; 33(49). doi: 10.3346/jkms.2018.33.e323. DOI: https://doi.org/10.3346/jkms.2018.33.e323

Malinowski KP and Kawalec P. The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2015 Mar; 15(2): 285-300. doi: 10.1586/14737167.2015.1001370. DOI: https://doi.org/10.1586/14737167.2015.1001370

Fautrel B, Benhamou M, Breban M, Roy C, Lenoir C, Trape G et al. Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial. Annals of the Rheumatic Diseases. 2010 Feb; 69(2): 424-7. doi: 10.1136/ard.2008.103887. DOI: https://doi.org/10.1136/ard.2008.103887

Bae SC, Cha JH, Choe JY, Choi SJ, Cho SK, Chung WT et al. Productivity loss of rheumatoid arthritis patients according to the their stages of the disease activity score. Journal of Rheumatic Diseases. 2018 Apr; 25(2): 122-30. doi: 10.4078/jrd.2018.25.2.122. DOI: https://doi.org/10.4078/jrd.2018.25.2.122

Jeon SH, Leem JH, Park SG, Heo YS, Lee BJ, Moon SH et al. Association among working hours, occupational stress, and presenteeism among wage workers: results from the Second Korean Working Conditions Survey. Annals of Occupational and Environmental Medicine. 2014 Dec; 26: 1-8. doi: 10.1186/2052-4374-26-6. DOI: https://doi.org/10.1186/2052-4374-26-6